In Brief: Boston Scientific/Heart Technology
This article was originally published in The Gray Sheet
Executive Summary
Boston Scientific/Heart Technology: Firms announce Oct. 16 that the Hart-Scott-Rodino waiting period for their proposed $500 mil. stock-swap merger has expired "without any request for more information from the U.S. Department of Justice or the Federal Trade Commission." The companies say that the expiration "eliminates any antitrust obstacle to closing the merger," which was announced in late August. Heart Technology shareholders are expected to vote on the deal in mid-December...
You may also be interested in...
Generic Or Innovator? Sandoz Sues CMS Over Potential Change In Rebate Classification
Sandoz argued against paying higher rebates for two of its drugs via the Centers for Medicare and Medicaid Services’ Medicaid drug rebate program in a US court six years after the suggestion was first made.
Ultrahuman Expands Wearable Medtech Production Into US After $35M Funding Round
Firm operating in London, India and United Arab Emirates says its “Ultra Factory” will open in Indiana within the next six months with end-to-end production based on its operational facility in India.
Cochlear’s Osia System Receives Expanded FDA Clearance For Use In Younger Children
Kids ages 5 and up now can benefit from Cochlear’s Osia implant and sound processor, indicated for hearing loss, mixed hearing loss and single-sided sensorineural deafness.